STTK vs. OCS, TVTX, KALV, ALT, VERV, LRMR, ANL, CMPS, ABUS, and ATXS
Should you be buying Shattuck Labs stock or one of its competitors? The main competitors of Shattuck Labs include Oculis (OCS), Travere Therapeutics (TVTX), KalVista Pharmaceuticals (KALV), Altimmune (ALT), Verve Therapeutics (VERV), Larimar Therapeutics (LRMR), Adlai Nortye (ANL), COMPASS Pathways (CMPS), Arbutus Biopharma (ABUS), and Astria Therapeutics (ATXS). These companies are all part of the "pharmaceutical preparations" industry.
Oculis (NASDAQ:OCS) and Shattuck Labs (NASDAQ:STTK) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, valuation, community ranking, risk, analyst recommendations, earnings, dividends and profitability.
22.3% of Oculis shares are owned by institutional investors. Comparatively, 58.7% of Shattuck Labs shares are owned by institutional investors. 10.5% of Shattuck Labs shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Shattuck Labs has a net margin of -3,133.63% compared to Shattuck Labs' net margin of -6,712.02%. Shattuck Labs' return on equity of -52.72% beat Oculis' return on equity.
Oculis presently has a consensus price target of $30.17, indicating a potential upside of 150.76%. Shattuck Labs has a consensus price target of $20.00, indicating a potential upside of 142.72%. Given Shattuck Labs' higher probable upside, equities research analysts clearly believe Oculis is more favorable than Shattuck Labs.
In the previous week, Oculis had 4 more articles in the media than Shattuck Labs. MarketBeat recorded 14 mentions for Oculis and 10 mentions for Shattuck Labs. Oculis' average media sentiment score of 0.57 beat Shattuck Labs' score of 0.16 indicating that Shattuck Labs is being referred to more favorably in the news media.
Oculis has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500. Comparatively, Shattuck Labs has a beta of 1.98, meaning that its share price is 98% more volatile than the S&P 500.
Shattuck Labs received 11 more outperform votes than Oculis when rated by MarketBeat users. However, 85.71% of users gave Oculis an outperform vote while only 76.32% of users gave Shattuck Labs an outperform vote.
Shattuck Labs has higher revenue and earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than Shattuck Labs, indicating that it is currently the more affordable of the two stocks.
Summary
Shattuck Labs beats Oculis on 9 of the 17 factors compared between the two stocks.
Get Shattuck Labs News Delivered to You Automatically
Sign up to receive the latest news and ratings for STTK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding STTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Shattuck Labs Competitors List
Related Companies and Tools
